Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma

NCT01941849 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Poor patient accrual

Conditions

Phaeochromocytoma
Paraganglioma

Interventions

DRUG: Vandetanib
RADIATION: 131I-mIBG

Sponsor

University College, London

Collaborators

[object Object]
[object Object]